Nanrilkefusp-alfa-SO-C101-DataSheet-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemENanrilkefuspalfaCat.No.:HY-P3379CASNo.:1416390-27-6Synonyms:SO-C101;SOT101作⽤靶点:InterleukinRelated作⽤通路:Immunology/Inflammation储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Nanrilkefuspalfa(SO-C101;SOT101)⼀种融合蛋⽩，IL-15和IL-15Rαsushi+结构域的选择性的强效激动剂。Nanrilkefuspalfa通过诱导记忆性CD8+T细胞、⾃然杀伤细胞、γ/δT细胞和⾃然杀伤T细胞的增殖和激活来抑制肿瘤。在各种⼩⿏肿瘤模型中，Nanrilkefuspalfa表现出出⾊的抗⿊⾊素瘤转移活性并抑制肿瘤⽣长。IC50&TargetIL-15IL-15Rα体外研究Nanrilkefuspalfa(0.01-10nM;7d)expandsandactivatesNKcellsubtypesfromhumanPBMCsinvitro[1].Nanrilkefuspalfa(1nM;20h)inducescytotoxicandtumorcell-killingactivityofhumanNKcellsubtypes[1].Nanrilkefuspalfa(0.1,1,and10nM;3dand7d)inducesexpressionofcytotoxicreceptorsNKp30,DNAM-1andNKG2DonhumanNKcells[1].体内研究Nanrilkefuspalfa(2mg/kg;s.c.;4consecutivedaysover2weeks)decreasestherateoftumordevelopmentandgrowthinmetastatickidneycancerRencamousemodelindependenceonnaturalkiller(NK)andCD8+Tcells.AndNanrilkefuspalfaalsoactivatesNKandCD8+TcytotoxicitygenesintheTC-1tumormodel[1].Nanrilkefuspalfa(1mg/kg;i.p.;4consecutivedaysover2weeks)with12.5mg/kganti-PD-1decreasestumorgrowthofestablishedTRAMP-C2tumorsandexpandsthepopulationsofCD8+TcellsandNKcells,butnotTregulatorycells(Tregs).AndNanrilkefuspalfaalsomediatesinhibitionofTRAMP-C2tumordevelopmentdependingmainlyonNKandCD8+Tcells[2].AnimalModel:MetastatickidneycancerRencamousemodel[1]Dosage:2mg/kg1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEAdministration:Subcutaneousinjection;for4consecutivedaysover2weeksResult:Decreasedtherateofthetumordevelopment.DecreasedthetumorgrowthofestablishedTC-1tumorsindependenceonNKandCD8+Tcells,butnotCD4+Tcells.Expandedimmunecellsintumor,lymphnodesandspleenandactivatesNKandCD8+TcytotoxicitygenesinTC-1tumormousemodel.AnimalModel:TRAMP-C2tumorsmousemodel[2]Dosage:1mg/kg;withorwithout12.5mg/kganti-PD-1Administration:Intraperitonealinjection;for4consecutivedaysover2weeksResult:Preventedtumordevelopmentwithanti-PD-1inthemajorityofTRAMP-C2mouseanddelaystumorgrowthafterre-challenge.REFERENCES[1].AntosovaZ,etal.SOT101inducesNKcellcytotoxicityandpotentiatesantibody-dependentcellcytotoxicityandanti-tumoractivity.FrontImmunol.2022Oct10;13:989895.[2].AdkinsI,etal.SO-C101displaysstronganti-tumoreffectinTC-1andTRAMP-C2tumormiceandincombinationwithPD-1blockadepreventstumordevelopmentinaNKandCD8+Tcellsdependentmanner[J].CancerResearch,2020,80(16_Supplement):6686-6686.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedica